Scarica l'app Stockscreener
1.265
3.81%
-0.065
Fibrobiologics Inc Borsa (FBLG) Ultime notizie
FibroBiologics Expands At-The-Market Equity Offering Capacity - TipRanks
FibroBiologics (NASDAQ: FBLG) expands $7.5M at-the-market stock offering - Stock Titan
FibroBiologics (NASDAQ: FBLG) expands ATM capacity to $7.5M under S-3 - Stock Titan
Exclusive: FibroBiologics targets 2026 data readout after trial progress for diabetic foot ulcer study - MSN
EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study - Sahm
FibroBiologics begins patient enrollment for diabetic foot ulcer trial - Investing.com
FibroBiologics begins patient enrollment for diabetic foot ulcer trial By Investing.com - Investing.com Canada
33 million people have diabetic foot ulcers. FibroBiologics starts a trial - Stock Titan
FibroBiologics CEO Issues Letter to Shareholders - 富途牛牛
FibroBiologics Grants Stock Options to Key Executives - TipRanks
FibroBiologics grants stock options to CEO Pete O’Heeron and CFO Jason D. Davis - TradingView
[8-K] FibroBiologics, Inc. Reports Material Event - Stock Titan
FibroBiologics (FBLG) seeks approval for warrant shares and 2026 equity incentive plan - Stock Titan
FibroBiologics reports preclinical burn wound treatment results _newTouch_By Investing.com - Investing.com South Africa
FibroBiologics (FBLG) CEO receives 92,410 options vesting over 4 years - Stock Titan
FibroBiologics (FBLG) CSO granted 61,607 stock options at $1.38 - Stock Titan
FibroBiologics (FBLG) CFO awarded 61,607 stock options at $1.38 - Stock Titan
FibroBiologics grants options to general counsel | FBLG Insider Trading - Stock Titan
FibroBiologics reports preclinical burn wound treatment results By Investing.com - Investing.com Australia
FibroBiologics reports preclinical burn wound treatment results - Investing.com
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring - The Manila Times
In mice, a topical cell treatment eased burn inflammation in 8 days - Stock Titan
FibroBiologics releases first batch of diabetic ulcer drug By Investing.com - Investing.com South Africa
Maxim Group Downgrades FibroBiologics(FBLG.US) to Hold Rating - Moomoo
FibroBiologics releases first batch of diabetic ulcer drug - Investing.com
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial - The Manila Times
Diabetic foot ulcer trial nears enrollment as drug batch clears tests - Stock Titan
FibroBiologics (FBLG) CSO Khoja buys $11k in stock - Investing.com
Certain Common Stock of FibroBiologics, Inc. are subject to a Lock-Up Agreement Ending on 3-MAY-2026. - marketscreener.com
Certain Stock Options of FibroBiologics, Inc. are subject to a Lock-Up Agreement Ending on 3-MAY-2026. - marketscreener.com
FibroBiologics Warns of ‘Going Concern’ Risk as Losses Mount and Funding Outlook Darkens - TipRanks
FibroBiologics Launches New At-The-Market Equity Offering - TipRanks
Regenerative medicine company FibroBiologics (stock code: FBLG) recently filed documents with the U.S. Securities and Exchange Commission (SEC), announcing that it has signed an At Market Issuance (ATM) agreement. - Bitget
[424B5] FibroBiologics, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
FibroBiologics (NASDAQ: FBLG) sets up $6,150,000 at-the-market stock program - Stock Titan
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update - The Manila Times
FibroBiologics Reports Q1 2026 Financial Results and Corporate Updates on Clinical Advancements - Quiver Quantitative
FibroBiologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
FibroBiologics (FBLG) low cash, $5M loss and going concern risk - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Preclinical psoriasis data from FibroBiologics heads to Chicago meeting - Stock Titan
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026 - The Manila Times
FibroBiologics (FBLG) price target decreased by 76.25% to 19.38 - MSN
Exclusive: FibroBiologics moves forward with human trial for diabetic foot ulcer therapy - MSN
FibroBiologics (FBLG) price target increased by 1,584.21% to 81.60 - MSN
Return on invested capital % of FibroBiologics, Inc. – LSX:A426UV - TradingView
FibroBiologics (FBLG) asks shareholders to OK March warrant issuances, equity plan - Stock Titan
FibroBiologics regains Nasdaq compliance on listing standards By Investing.com - Investing.com India
FibroBiologics regains Nasdaq compliance on listing standards - Investing.com
FibroBiologics Secures Nasdaq Listing Compliance, Under Monitoring - TipRanks
Fibrobiologics compliant with all Nasdaq listing requirements - marketscreener.com
FibroBiologics confirms Nasdaq compliance; listing matter closed, one-year monitors remain - TradingView
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):